R&D channel feed – Endpoints News

R&D channel feed

Pfizer, Sarepta and two others suggest Duchenne drug safety issues tied to "class effect"

4 years ago

Moderna starts up third HIV vaccine trial, partnering with IAVI to study its shot in Africa

4 years ago

Less than two years after nine-figure IPO, Applied Molecular Transport cuts back on staff, pipeline efforts

4 years ago

Genomics biotech undergoes a facelift, rebranding from Clover to Character Biosciences

4 years ago

Cytokinetics' long and winding road to develop its lead heart drug will face an adcomm this fall

4 years ago

Amidst R&D reshuffle, Vertex expands its presence in Boston, aiming to become number one

4 years ago

Bear market forces Scholar Rock, potentially years away from pivotal SMA data, to lay off a fourth of its staff

4 years ago

Agios CSO to depart amid layoffs as biotech looks for new drugs to license or acquire

4 years ago

Aldevron and Inscripta ink manufacturing deal for CRISPR Type-V nuclease

4 years ago

AstraZeneca, Avillion detail the pivotal combo asthma data they're taking to the FDA

4 years ago

Chinese Alzheimer's drugmaker says lack of funding, Covid outbreak forced it to shutter international PhIII

4 years ago

Staying in the back seat to Keytruda, Bristol Myers reports another pivotal setback in urothelial cancer

4 years ago

Roche's TIGIT fallout causes GSK and iTeos to re-think their own I/O candidate

4 years ago

Quashing blockbuster hopes, FDA spurns UCB’s IL-17 drug for plaque psoriasis

4 years ago

Eylea keeps its lead in the retinal space as physicians remain hesitant on Roche's Susvimo — report

4 years ago

Caribou aces its first round of human data in search of an off-the-shelf CAR-T breakthrough

4 years ago

Rinvoq passes PhIII maintenance study for Crohn's disease, potentially setting the stage for label expansion

4 years ago

Bristol Myers builds the case for psoriasis hopeful as it waits in regulatory limbo

4 years ago

A week after disclosing layoffs, BridgeBio nets a $90M upfront cancer R&D pact with Bristol Myers

4 years ago

Takeda boots a top prospect out of its late-stage pipeline while another is delayed by war, lockdown

4 years ago

The collapse of SKYSCRAPER-01 is casting a pall over all the TIGITs. Are we in for another I/O fiasco?

4 years ago

Iterum says FDA is in 'general alignment' on proposed new PhIII for rejected uUTI drug

4 years ago

AstraZeneca and Sanofi sharpen RSV pitch with new analyses, but how much weight will FDA give them?

4 years ago

Roche goes 0-2 in the high-stakes race to get a TIGIT through PhIII and onto the market

4 years ago

First page Previous page 135 136 137138139 140 141 Next page Last page